Kane Biotech Inc.
KNBIF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,296.8% | -94.4% | 66% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 41.9% | 73.5% | 53% | 35.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -178.2% | -2,171% | -110.5% | -264.1% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 293% | -3,379% | -145.8% | -286.4% |
| EPS Diluted | -0.024 | -0.036 | -0.033 | -0.041 |
| % Growth | 34.3% | -7.8% | 18.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |